Hepagam B Purple Book BLA 125035

BLA number
125035
Proprietary names
Hepagam B
Proper names
Hepatitis B Immune Globulin (Human)
Applicant
Kamada Ltd.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Hepagam BHepatitis B Immune Globulin (Human)351(a)>1560IU/5MLInjectionIntramuscularSingle-Dose VialRxLicensed2006-01-27
002Hepagam BHepatitis B Immune Globulin (Human)351(a)>312IU/MLInjectionIntramuscularSingle-Dose VialRxLicensed2006-01-27

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-06-01U001Hepagam B351(a)RxKamada Ltd.
2023-06-01U002Hepagam B351(a)RxKamada Ltd.
2022-09-01U001Hepagam B351(a)RxKamada Ltd.
2022-09-01U002Hepagam B351(a)RxKamada Ltd.
2022-01-01U001Hepagam B351(a)RxSaol Therapeutics Research Limited
2022-01-01U002Hepagam B351(a)RxSaol Therapeutics Research Limited
2021-09-01U001Hepagam B351(a)RxSaol Therapeuctics Research Limited
2021-09-01U002Hepagam B351(a)RxSaol Therapeuctics Research Limited
2021-05-01U001Hepagam B351(a)RxSaol Therapeuctics Research Limited
2021-05-01U002Hepagam B351(a)RxSaol Therapeuctics Research Limited
2020-08-01R001Hepagam B351(a)RxSaol Therapeuctics Research Limited
2020-08-01R002Hepagam B351(a)RxSaol Therapeuctics Research Limited

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Hepagam B351(a)RxLicensed2006-01-27
2020-08-01002Hepagam B351(a)RxLicensed2006-01-27